JP2021528460A - パーキンソン病の治療におけるマンヌロン二酸組成物の使用 - Google Patents

パーキンソン病の治療におけるマンヌロン二酸組成物の使用 Download PDF

Info

Publication number
JP2021528460A
JP2021528460A JP2020572820A JP2020572820A JP2021528460A JP 2021528460 A JP2021528460 A JP 2021528460A JP 2020572820 A JP2020572820 A JP 2020572820A JP 2020572820 A JP2020572820 A JP 2020572820A JP 2021528460 A JP2021528460 A JP 2021528460A
Authority
JP
Japan
Prior art keywords
total weight
composition
acid
mannuronedioic
diacid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020572820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528460A5 (https=
JPWO2020001640A5 (https=
Inventor
ゲン、メイユ
シン、シャンリャン
ドゥ、シャオグアン
チャン、チェンチン
ディン、ジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Shanghai Green Valley Pharmaceutical Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Publication of JP2021528460A publication Critical patent/JP2021528460A/ja
Publication of JP2021528460A5 publication Critical patent/JP2021528460A5/ja
Publication of JPWO2020001640A5 publication Critical patent/JPWO2020001640A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020572820A 2018-06-29 2019-06-28 パーキンソン病の治療におけるマンヌロン二酸組成物の使用 Pending JP2021528460A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810713411.3A CN110652516A (zh) 2018-06-29 2018-06-29 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
CN201810713411.3 2018-06-29
PCT/CN2019/093803 WO2020001640A1 (zh) 2018-06-29 2019-06-28 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用

Publications (3)

Publication Number Publication Date
JP2021528460A true JP2021528460A (ja) 2021-10-21
JP2021528460A5 JP2021528460A5 (https=) 2022-07-05
JPWO2020001640A5 JPWO2020001640A5 (https=) 2022-07-05

Family

ID=68984646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572820A Pending JP2021528460A (ja) 2018-06-29 2019-06-28 パーキンソン病の治療におけるマンヌロン二酸組成物の使用

Country Status (7)

Country Link
US (1) US11406654B2 (https=)
EP (1) EP3815691A4 (https=)
JP (1) JP2021528460A (https=)
KR (1) KR20210038874A (https=)
CN (1) CN110652516A (https=)
AU (1) AU2019296851A1 (https=)
WO (1) WO2020001640A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796243B (zh) * 2021-01-27 2024-04-05 中国海洋大学 一种甘露糖醛酸和益母草碱的药物组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530718A (ja) * 2004-03-24 2007-11-01 中国海洋大学 アルギンオリゴ糖及びその誘導体、並びにそれらの調製と用途
JP2016507575A (ja) * 2013-02-12 2016-03-10 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン
CN106344592A (zh) * 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用
JP2020507619A (ja) * 2016-12-30 2020-03-12 シャンハイ、グリーン、バレー、ファーマスーティカル、カンパニー、リミテッドＳｈａｎｇｈａｉ Ｇｒｅｅｎ Ｖａｌｌｅｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． マンヌロン二酸の組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101301310B (zh) * 2007-05-08 2011-11-02 首都医科大学 褐藻多糖硫酸酯在预防和治疗帕金森病中的用途
CN103405468B (zh) * 2013-08-16 2015-08-19 中国海洋大学 一种低分子量甘露糖醛酸寡糖在制备预防或治疗帕金森症的药物或保健品中的应用
CN103800348B (zh) * 2014-03-13 2015-07-01 中国科学院海洋研究所 甘露葡萄糖醛酸寡糖在制备治疗或预防帕金森病和/或老年痴呆药物和/或保健品中的应用
CN103948611B (zh) * 2014-03-31 2016-03-02 青岛海洋生物医药研究院股份有限公司 低聚古罗糖醛酸盐在制备防治帕金森症药物或制品中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530718A (ja) * 2004-03-24 2007-11-01 中国海洋大学 アルギンオリゴ糖及びその誘導体、並びにそれらの調製と用途
JP2016507575A (ja) * 2013-02-12 2016-03-10 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン
CN106344592A (zh) * 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用
JP2020507619A (ja) * 2016-12-30 2020-03-12 シャンハイ、グリーン、バレー、ファーマスーティカル、カンパニー、リミテッドＳｈａｎｇｈａｉ Ｇｒｅｅｎ Ｖａｌｌｅｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． マンヌロン二酸の組成物

Also Published As

Publication number Publication date
WO2020001640A1 (zh) 2020-01-02
US20210260089A1 (en) 2021-08-26
US11406654B2 (en) 2022-08-09
AU2019296851A8 (en) 2021-07-01
EP3815691A4 (en) 2022-04-27
KR20210038874A (ko) 2021-04-08
EP3815691A1 (en) 2021-05-05
AU2019296851A1 (en) 2021-01-28
CN110652516A (zh) 2020-01-07

Similar Documents

Publication Publication Date Title
JP6977059B2 (ja) マンヌロン二酸の組成物
JP2021528460A (ja) パーキンソン病の治療におけるマンヌロン二酸組成物の使用
JP2021529195A (ja) 炎症の治療におけるマンヌロン二酸組成物の使用
JP2021528459A (ja) 糖尿病の治療におけるマンヌロン二酸組成物の使用
US11406653B2 (en) Use of mannuronic diacid composition in treatment of pain
US11406651B2 (en) Use of mannuronic diacid composition in treatment of vascular dementia
HK40014917A (en) Use of a composition of oligomeric mannuronic diacid for treating parkinson's disease
HK40016250A (en) Use of a composition of mannuronic diacids in the treatment of diabetes
HK40016251A (en) Use of a composition of mannuronic diacids in the treatment of pain
HK40014915A (en) Use of a composition of oligomeric mannuronic diacid for treating inflammation
JP2022543641A (ja) Ｔｈ１優位関連疾患の治療におけるマンヌロン酸オリゴ糖またはそれを含んでなる組成物の使用
EA041420B1 (ru) Композиции маннуроновой дикислоты, способы ее получения и использования

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231205